Press Corner

PRESS ENQUIRIES

➜ Contact us via e-mail

OUR HISTORY

➜ From the lab to the patient

Last updated: August 3, 2020

 

PRESS RELEASES

Posts Are Coming Soon
Stay tuned...
 

PHOTOS & LOGOS

Capture d’écran 2020-02-24 à 13.00.17.pn
Do.png
20200624-DxPG80-VUE-3D _v05.jpg
Capture d’écran 2020-02-17 à 11.51.29.pn
Capture d’écran 2020-02-17 à 11.51.23.pn

Icone Logo

format: Illustrator picture

 

VIDEOS

Dominique Joubert Presentation

 

Video length : 2:30'

French (English subtitle)

Royalty-free video on demand

​

From the lab to the patient

Performing a scientific demonstration and bringing it to the patient is the dream of every scientist that Dominique Joubert is living. 

The scientific demonstration in question here is a major precision: to be able to detect cancer and to reverse the tumour process, in other words, to "bring back to normal cells that were cancerous"

.

Our Montpellier laboratory

 

Video length : 1:01'

Video without audio

royalty-free video on demand

​

​

Lyon CHU laboratory

 

Video length : 3:06'

Video without audio

royalty-free video on demand

​

​

It's time to control cancer

Contact us

 

IT'S TIME TO CONTROL CANCER

It has been shown that hPG80 (Circulating Progastrin) is produced by all cancer cells across all stages, but in quantities 100 to 1000 times higher by cancer stem cells which are considered to be primarily responsible for recurrence and metastasis. 

​

hPG80 is released from the tumor and becomes detectable in the blood, making hPG80 the only blood biomarker that not only detects the presence but also the activity of the tumor.

​

16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.

​

Detection and assay of hPG80 can provide Physicians with new information that can help them:

  • Evaluate treatment efficacy,

  • Monitor risk of relapse,

  • Assess Minimal Residual Disease (MRD) risk,

  • Diagnose cancers which have no biomarker and for at-risk populations, in order to detect early enough the tumor, easily located in these populations.

ECS-Progastrin is a subsidiary of Progastrine Invest SCSp (Cancer Control Funding Fund)  11 côte d'Eich, L1450, Luxemburg City - Grand Duchy of Luxemburg

MAINS LOCATIONS AND OFFICES:

​

  • LUXEMBURG

  • SWITZERLAND

  • FRANCE

  • UNITED ARAB EMIRATES

  • UNITED STATES OF AMERICA

MAINS COMPANIES:

​

  • ECS PROGASTRIN

  • ECS PROGASTRIN LAB

  • PROGASTRINE ET CANCERS

  • EUROBIODEV

  • PROGASTRIN MANUFACTURING

Progastrine Invest SCSp and its subsidiaries:

  • focus on innovation in cancer diagnosis, localization, follow-up and treatment,

  • hold the rights to the first hPG80 (Circulating Progastrin) assay which is now available,

  • hold the rights to the cancer therapy project with an anti-hPG80 antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2015-2021 ECS-Progastrin ® . All rights reserved